KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Sarepta Therapeutics (SRPT) over the last 9 years, with Q2 2025 value amounting to $152.6 million.

  • Sarepta Therapeutics' Cost of Revenue rose 24248.06% to $152.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $421.1 million, marking a year-over-year increase of 13884.5%. This contributed to the annual value of $319.1 million for FY2024, which is 11224.73% up from last year.
  • As of Q2 2025, Sarepta Therapeutics' Cost of Revenue stood at $152.6 million, which was up 24248.06% from $132.3 million recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' Cost of Revenue peaked at $152.6 million during Q2 2025, and registered a low of $19.5 million during Q2 2021.
  • Its 5-year average for Cost of Revenue is $50.5 million, with a median of $37.0 million in 2023.
  • In the last 5 years, Sarepta Therapeutics' Cost of Revenue crashed by 971.29% in 2023 and then soared by 24248.06% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Cost of Revenue (Quarter) stood at $31.7 million in 2021, then decreased by 2.98% to $30.8 million in 2022, then skyrocketed by 43.43% to $44.2 million in 2023, then skyrocketed by 199.49% to $132.3 million in 2024, then grew by 15.31% to $152.6 million in 2025.
  • Its Cost of Revenue stands at $152.6 million for Q2 2025, versus $132.3 million for Q4 2024 and $91.7 million for Q3 2024.